Indian journal of Medical Biochemistry

Register      Login

VOLUME 21 , ISSUE 1 ( January-June, 2017 ) > List of Articles

ORIGINAL ARTICLE

Immune Response Profiling of Patients with Anogenital Warts

Manjula Singh, Deepshi Thakral, Hemanta K Kar, Narayan Rishi, Dipendra K Mitra

Citation Information : Singh M, Thakral D, Kar HK, Rishi N, Mitra DK. Immune Response Profiling of Patients with Anogenital Warts. Indian J Med Biochem 2017; 21 (1):11-16.

DOI: 10.5005/jp-journals-10054-0011

License: CC BY 3.0

Published Online: 00-06-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Singh M, Thakral D, Kar HK, Rishi N, Mitra DK. Immune Response Profiling of Patients with Anogenital Warts. Indian J Med Biochem 2017;21(1):11-16.


PDF Share
  1. A retrospective study of the pattern of sexually transmitted diseases during a ten-year period. Indian J Dermatol Venereol Leprol 2005 Sep-Oct;71(5):333–337.
  2. Diagnostic pathology: infectious diseases. Philadelphia (PA): Elsevier Health Sciences; 2015. p. 40.
  3. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995 Aug;33(8):2058–2063.
  4. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol (Berl) 2004 Feb;193(1):35–44.
  5. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003 Jun;36(11):1397–1403.
  6. Prevalence of penile human papillomavirus DNA in husbands of women with and without cervical neoplasia: a study in Spain and Colombia. J Infect Dis 1997 Aug;176(2):353–361.
  7. Burden of human papillomavirus infection and related co-morbidities in men: implications for research, disease prevention and health promotion among Hispanic men. P R Health Sci J 2010 Sep;29(3):232–240.
  8. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007 Oct;196(8):1128–1136.
  9. Genital warts treated by photodynamic therapy. Skinmed 2007 Nov-Dec;6(6):295–297.
  10. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008 May;109(2 Suppl):S15–S21.
  11. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses 2013 Nov;5(11):2624–2642.
  12. Immune response against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother 2012 Dec;18(6): 807–815.
  13. Cellular subsets and epithelial ICAM-1 and HLA-DR expression in human papillomavirus infection of the vulva. Acta Derm Venereol 1994 Jan;74(1):45–50.
  14. Immunohistochemical and ultrastructural features of Langerhans cells in condyloma acuminatum. J Cutan Pathol 2008 Jan; 35(1):15–20.
  15. Decreased Langerhans cell responses to IL-36□: altered innate immunity in patients with recurrent respiratory papillomatosis. Mol Med 2014 Aug;20:372–380.
  16. Local accumulation of FOXP3+ regulatory T cells: evidence for an immune evasion mechanism in patients with large condylomata acuminate. J Immunol 2008 Jun;180(11):7681–7686.
  17. Immunological study on genital wart patients in Babylon Province – Iraq. Med J Babylon 2015 May;12(1):233–239.
  18. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997 Feb;89(3):245–250.
  19. Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia. Hum Immunol 2012 Sep;73(9):920–926.
  20. Serological studies with human papova (wart) virus. J Hyg (Lond) 1970 Sep;68(3):479–490.
  21. Characterisation of the virus found in human genital warts. Microbios 1969;3:225–233.
  22. The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women. Am J Obstet Gynecol 1984 Oct;150(3):300–308.
  23. Prevalence of HPV DNA in cervical specimens in women with renal transplants: a comparison with dialysis-dependent patients and patients with renal impairment. Nephrol Dial Transplant 1994 Jan;9(4):416–420.
  24. Skin cancer and warts in immunosuppressed renal transplant recipients. Recent Results Cancer Res 1995 Feb;139:69–86.
  25. Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. Eur J Gynaecol Oncol 1999; 20(2):127–130.
  26. Effect of HIV infection on the natural history of anal human papillomavirus infection. AIDS 1998 Jul;12(10):1177–1184.
  27. Association of human immunodeficiency virus and anal human papillomavirus infection among homosexual men. Arch Intern Med 1992 Aug;152(8):1673–1676.
  28. Prevalence of anal human papillomavirus infection and anal cytologic abnormalities in HIV-seropositive women. AIDS 1996 Dec;10(14):1641–1647.
  29. Anal intraepithelial neoplasia and anal papillomavirus infection among homosexual males with group IV HIV disease. JAMA 1990 Jun;263(21):2911–2916.
  30. Anal cytological abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease. Genitourin Med 1997 Jun;73(3):174–180.
  31. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998 Feb;177(2):361–367.
  32. Human papillomavirus infections of the genital region in human immunodeficiency virus seropositive women: integration of type 16 correlates with rapid progression. Eur J Gynaecol Oncol 1994 Jan;15(1):50–58.
  33. A matched prospective study of human immunodeficiency virus serostatus, human papillomavirus DNA, and cervical lesions detected by cytology and colposcopy. Infect Dis Obstet Gynecol 1999 Jan;7(3):158–164.
  34. A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol 1998 May;178(5):982–986.
  35. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997 Nov;337(19):1343–1349.
  36. Autocrine growth limitation of human papillomavirus type 16-harboring keratinocytes by constitutively released tumor necrosis factor-alpha. J Immunol 1992 Oct;149(8):2702–2708.
  37. Increased tumorigenicity of human keratinocytes harboring human papillomavirus type 16 is associated with resistance to endogenous tumor necrosis factor-alpha-mediated growth limitation. Int J Cancer 1994 Feb;56(4):593–598.
  38. Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells. J Virol 1990 Oct;64(10):4767–4775.
  39. In vitro assay of cell-mediated immunity to human wart antigen. Br J Dermatol 1974 May;90(5):531–534.
  40. In vitro lymphocyte stimulation by wart antigen in man. Br J Dermatol 1976 May;94(5):523–527.
  41. Cell-mediated immunity (CMI) to human wart virus and wart-associated tissue antigens. Clin Exp Immunol 1976 Dec;26(3):419–424.
  42. Specific immunity in patients suffering from recurring warts before and after repetitive intradermal tests with human papilloma virus. Br J Dermatol 1997 Oct;97(4):365–370.
  43. A comparative study of delayed hypersensitivity skin reactions and antibodies to human papilloma virus (HPV). Clin Exp Immunol 1997 Aug;29(2):240–246.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.